PharmEasy IPO  received SEBI nod. The company has interesting business of digital healthcare.Lets study about its business and IPO particulars

PharmEasy Company Details
PharmEasy ( API Holdings) is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report. It operates an integrated, end-to-end business that aims to provide solutions for healthcare needs of consumers across the following critical stages
A. providing digital tools and information on illness and wellness,
B. offering teleconsultation,
C. offering diagnostics and radiology tests, and
D. delivering treatment protocols including products and devices.
Its custom-built proprietary technology, unified data platforms, supply chain capabilities, and deep understanding of the dynamic interplay between the various sub-segments of India’s healthcare market are the capabilities that differentiate it.

These capabilities enable it to provide each stakeholder in the healthcare value-chain, viz.:
(a) channel (wholesalers, retailers and chemists / institutions),
(b) consultants (and hospitals), diagnostic and radiology labs,
(c) consumers, and
(d) companies (pharmaceutical, nutraceutical, medical devices)
with the technology tools and capabilities to solve their challenges, while also enabling them to benefit from an interconnected network. At the same time, they also enable it to build a scaled presence, allowing its platform to reach a wide base of stakeholders across the length and breadth of this country.

Its businesses have a presence across the country, with last-mile capabilities to deliver in over 18,587 pin codes (for June 2021) via PharmEasy marketplace, allowing it the ability to provide access in an affordable manner to the common man. Its platforms have scaled across urban, semi-urban and rural India, with an ability to serve people across income groups and geographies.
For more information, click www.apiholdings.in

The Promoters of PharmEasy
The Company does not have an identifiable promoter

PharmEasy IPO Main Objects
The Offer comprises the Fresh Issue by the Company and an Offer for Sale by the Selling Shareholders.
The Net Proceeds are proposed to be utilised towards
1.Prepayment or repayment of all or a portion of certain outstanding borrowings availed by the Company and certain of our Subsidiaries Rs 1929 cr
2.Funding organic growth initiatives Rs 1259 cr
3.Pursuing inorganic growth through acquisitions and other strategic initiatives Rs. 1500 cr

PharmEasy IPO Details
Issue Type: Book Built Issue IPO
Issue : up to ? Shares /Rs 6250 Crore
* Fresh Issue of (?) Sh/ Rs.6250 Cr
* Offer for Sale Up to 16,044,709 Sh/ Rs. ?Cr

PharmEasy IPO Financial & Analytical Ratios
Earnings per Share 2019-20 Rs (1.17)
Earnings per Share 2020-21,Rs ( 1.88)
Earnings per Share 2021-22 3M Rs (0.70)
Book Value of the Share as on 31.3.2021 Rs 8.00
Return on Net Worth: 19-20 (136.14) %
Return on Net Worth: 20-21: (18.50) %
Return on Net Worth: 20-21 3M : (7.34) %
Equity Shares prior to the IPO : 6,098,109,930 Shares
Equity Shares after the IPO : (?) Shares

PharmEasy IPO Peer Comparison:
There are no listed companies in India that are engaged in a business similar to that of this Company

#This is only coverage of News related to Grey Market . We donot deal in Grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.